Skip to main content
. 2018 Jun 4;8:163. doi: 10.3389/fonc.2018.00163

Figure 1.

Figure 1

Rituximab development timeline. Key milestones leading to the development of rituximab and additional CD20 monoclonal antibodies (mAbs) for use to treat B-cell non-Hodgkin lymphoma.